1.
PLus tHree interactive Post conference WorksHoPs
Wednesday 29tH aPriL 2020, sHeraton boston HoteL, boston, usa
HigHLigHts for 2020:
• Explore how digital connectivity is being used in the
PFS industry
• Gain insights into control strategies for DDC
developments
• Hear key regulatory updates from the FDA and
industry experts
• Understand how patient centricity is being
incorporated into device development
• New for 2020: Interactive workshop day
cHair for 2020:
Michael Song,
Senior Manager, Dosage Form Design and Development,
AstraZeneca
featured 2020 sPeakers incLude:
• Tina Kiang, Director, Division of Drug Delivery and General
Hospital Devices, and Human Factors, Food and Drug
Administration
• Alie Jahangir, Senior Manager, Combination Products and
Emerging Technologies, Janssen Pharmaceutical
• Delma L Broussard, Director, Medical Device & Combination
Products PV Expert, CSL Behring
• Susan Neadle, Sr. Director, Global Value Chain Quality Design,
Head, J&J Combination Products CoP, Johnson & Johnson
• Diane Doughty, Senior Scientist, Dosage Form Design &
Development, AstraZeneca
• Jennifer Hefele Wald, Director Global Regulatory Affairs Devices
& Combination Products, Pfi zer
• Heather L. Guerin, Associate Director, Regulatory Affairs - CMC,
Janssen
• Krystin Meidell, Manager, Regulatory Affairs CMC Medical
Devices and Combination Products, Biogen
• Michael Friedman, Combination Product Lead, Amgen
... And Many More!
www.pfsamericas.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE @sMiPHarM
#smipfsusa
Sheraton Boston Hotel, Boston, USA
SMi Group Proudly Present the 7th annual...
CONFERENCE:
27TH - 28TH
WORKSHOP DAY: 29TH
APRIL
2020Innovations in parenteral device and product development
Pre-Filled Syringes
East Coast
A: Combination Product Development
– A roadmap for success
Workshop Leader: Michael Song, Senior Manager,
Dosage Form Design and Development, AstraZeneca
08.30 - 12.00
B: Drug Delivery Device Testing Solutions
Workshop Leader: Michael Goehring, Medical &
Pharmaceutical Industry Manager, ZwickRoell
13.00 - 15.30
C: How to pass a Human Factors
Validation study
Workshop Leader: Marc Egeth, PhD, Senior Director,
Core Human Factors, Inc. and Pati Anderson, Mse,
Senior Associate, Core Human Factors, Inc.
16.00 - 18.20
REGISTER By 13TH DECEMBER AND SAVE $400
REGISTER By 31ST JANUARy AND SAVE $300
REGISTER By 28TH FEBRUARy AND SAVE $200
sPonsored by

2.
08.00 Registration & Coffee
09.00 Chair’s Opening Remarks
Michael Song, Senior Manager, Dosage Form Design and
Development, AstraZeneca
digitaL connectivity in tHe Pfs industry
oPening address
09.10 Wearable and digital devices – a hybrid view between
pharmaceutical and medical devices
• How lessons learned from medical device can help with
wearable device development
• Electronics, batteries, and IEC requirements – let’s not
reinvent the wheel
• Testing approach for novel / unique devices
Michael Song, Senior Manager, Dosage Form Design and
Development, AstraZeneca
9.50 Digital health: The evolving regulatory landscape
• Overview of recent changes in regulation and guidance
• Case Study: Connected Integrated Injector
• Case Study: Sensor/App for Inhaler
• Case Study: Dose Calculator App
Krystin Meidell, Manager, Regulatory Affairs CMC Medical
Devices and Combination Products, Biogen
10.30 Morning Coffee – Sponsored by
11.00 Simulation driven analysis in Product development
• Cloud based Numerical simulation.
• Scripted simulation to achieve design optimization
Lin Li, Senior Consultant Engineer, Delivery Devices and
Connected Solutions, Eli Lilly and Company
drug Product forMuLation and controL strategies
11.40 Challenges and opportunities in developing a system-wide
stability program for combination products
• Combination Products
• Stability Indicating Attributes
• Design Control process
• End-to-End Stability
• Drug/Biologics- Device Interactions
Alie Jahangir, Senior Manager, Combination Products and
Emerging Technologies, Janssen Pharmaceuticals
12.20 Consideration for defi ning the administration procedure for
nano-dose drug in clinical studies
• Adsorption phenomenon
• Dose recovery considerations
• Mitigation strategies
Michael Zhou, Investigator, Pharmaceutical
Development- Sterile CoE, gsk
13.00 Networking Lunch
14.00 Technical overview of COP for prefi lled syringes
• Key properties of COP
• Case Study (New):
- Protein Adsorption of Abatacept – COP vs Glass
- Immunogenicity test of the aggregates
• Case Study: Protein Adsorption of Humira, Embrel,
Remicade – COP vs Glass
• Case Study: Protein Adsorption with/without Polysorbate
(Surfactant) – COP vs Glass
• Leachable data on COP syringes
Larry Atupem, Sr. Business Development Specialist,
Zeon Specialty Materials
14.40 Combination Product Risk Management
• Introduction of ICH Q9 and ISO 14971
• Challenges of completing a comprehensive Hazard
Analysis for combination products
• Design Risk Assessments for off the shelf components
• Integrating current drug development risk assessments to
meet ISO 14971 compliance
Tanner Barnes, Design Control Engineer II, Pfi zer
15.20 Qualifi cation and validation of VH2O2 industrial low
temperature terminal sterilizer process and equipment - Case
study on process control and monitoring
• Brief introduction to VH2O2 sterilization process, technology
and applications
• Discuss validation and meeting ISO14937 standard
requirements - and looking at the scenario of future VH2O2
specifi c standards
• Present the essential process variables forVH2O2 sterilization
• Case study on testing and comparing performance of
various hydrogen peroxide concentration measurement
methods – and proposing an applicable approach
Juha Mattila, Director, Sterilization Technologies,
STERIS Corporation
16.00 Afternoon Tea – Sponsored by
REGULATORy OUTLOOK – PART 1
sPotLigHt Presentation
16.30 A regulatory outlook and update of the
combination product industry
• Affect of TPLC re-organization in CDRH on combination
product review (premarket and compliance)
• New guidance updates
Tina Kiang, Director, Division of Drug Delivery and General
Hospital Devices, and Human Factors, Food and Drug
Administration
17.10 EU MDR impact on premarket regulatory requirements for
combination products
• Overview of new requirements of EU MDR Article 117,
which could result in signifi cant changes in practice, and
potential impact to product development timelines
• Collaborations between industry regulatory networks and
EMA and Notifi ed Bodies to clarify requirements
• Discussion of recognized issues in interpreting Article 117
requirements and potential paths forward to meet new
requirements
Heather L. Guerin, Associate Director, Regulatory Affairs -
CMC, Janssen
17.50 Chair’s Closing Remarks and Close of Day One
18.30 End of Day One Networking Dinner - Invitation Only
Register online at www.pfsamericas.com
Pre-Filled Syringes East Coast Conference
DAy ONE | MONDAy 27TH APRIL 2020 www.pfsamericas.com

3.
08.30 Registration & Coffee
09.00 Chair’s Opening Remarks
Michael Song, Senior Manager, Dosage Form Design and
Development, AstraZeneca
Lifecycle Management for Combination Products
OPENING ADDRESS
09.10 Combination products integrated development
• Combination Products Regulations are evolving globally
• One consistent undercurrent to this dynamic regulatory
environment is the drive for successful practices and control
strategies throughout the combination product lifecycle, to
assure public health, ensuring risk is commensurate with product
complexity and patient needs
• In this presentation we’ll review combination products integrated
development and risk management considerations and
essential performance requirements to support robust product
development and lifecycle management
Susan Neadle, Sr. Director, Global Value Chain Quality
Design, Head, JJ Combination Products CoP,
Johnson Johnson
09.50 Combination product lifecycle management
• Why is it important to incorporate risk management and
design controls into the LCM of Combination products?
• How to manage change through design controls
• Use of platforms for optimization of development time
and costs
• Regulatory standards to consider
Michael Friedman, Combination Product Lead, Amgen
10.30 Morning Coffee – Sponsored by
11.00 Lifecycle management of combination products
- a regulatory perspective
• Regulatory’s role in the product change assessments and
DHF deliverables
• Handling legacy combination products
• What should be submitted for legacy and new
combination products?
Jennifer Hefele Wald, Director Global Regulatory Affairs
Devices Combination Products, Pfizer
Regulatory Outlook – Part 2
11.40 Regulatory Perspective on Human Factors Requirements for
Combination Products
• Overview of human factors topics including platform
approaches, training programs, and Instructions for use
• Importance of risk analysis and risk considerations
in development of human factors studies and
communication of results
• Best practices for incorporating human factors studies
results into regulatory filings
Heather L. Guerin, Associate Director, Regulatory Affairs -
CMC, Janssen
12.20 FDA postmarketing safety reporting for combination
products guidance
• Reporting requirements for combination products
under PMSR final rule
• Overview of report types based on constituent parts
• Hypothetical examples of report types
Delma L Broussard, Director, Medical Device Combination
Products PV Expert, CSL Behring
13.00 Networking Lunch
Device Development
PANEL DISCUSSION
14.00 Combination products evolving trends
• What are some of the significant challenges that
people face in implementation of combination product
regulations?
• Is there anything uniquely challenging from a drug-led
manufacturer versus a device-led manufacturer?
• Can you comment on Post-Marketing Safety Reporting for
Combination Products as it relates to risk management?
Panel Moderator: Susan Neadle, Sr. Director, Global Value
Chain Quality Design, Head, JJ Combination Products CoP,
Johnson Johnson
Panelists: Jennifer Hefele Wald, Director Global Regulatory
Affairs Devices Combination Products, Pfizer
Delma L Broussard, Director, Medical Device Combination
Products PV Expert, CSL Behring
Alie Jahangir, Senior Manager, Combination Products and
Emerging Technologies, Janssen Pharmaceuticals
Leonel Vanegas, President/Principal, Resmedica
14.40 Latest date of oxycapt multilayer plastic vial syringe
• Comparison among OXYCAPT, COP and Glass
• Excellent Oxygen Ultraviolet Barrier
• Oxidation and Aggregation Studies of Antibody
• Development of Staked Needle Syringe
Shota Arakawa, Researcher, Mitsubishi Gas
Chemical Company, Inc.
15.20 Afternoon Tea – Sponsored by
15.50 Design considerations for optimizing the user experience
of prefilled syringes and injection devices
• Device features of prefilled syringes and injection devices
to support candidate device selection
• Design considerations for minimizing pain upon injection
• Case study of exploratory clinical study to evaluate
injection parameters
Diane Doughty, Senior Scientist, Dosage Form Design
Development, AstraZeneca
16.30 How quality can help drug-device combination teams
become agile in a changing regulatory landscape
• The role of quality and CMC during drug-device
combination products evolution
• Five steps towards becoming agile and flexible
anticipating formulation changes before NDA/BLA filings
• From pre-filled into a different presentation format after
marketing approvals
• Life-Cycle Management considerations (e.g. data you’ll
need to demonstrate to the regulatory agencies)
Leonel Vanegas, President/Principal, Resmedica
17.10 Chair’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Pre-Filled Syringes East Coast Conference
Day TWO | TUESday 28th APRIL 2020 www.pfsamericas.com
Hear from pharma and regulatory KOLs
leading the way in Pre-Filled Syringes
Engage in case studies, regulatory outlooks
and panel discussions exploring the industry
We keep networking at the forefront when it
comes to our attendees. Expand your
community, benefit from the right people and
secure future collaborations

4.
Overview of the workshop:
As more and more drug products are being developed
as combination products, device development plays
a critical role. To successfully develop a combination
product, it requires collaboration and consideration from
multiple angels.
In this workshop we will dive into each of these factors
from primary container and device selection to how to
manufacturing considerations and ways to platform and
streamline development activities without running into
regulatory risks. Some of the areas we will explore include
• Drug product and primary container interaction and
impact on device selection and development
• How to select the right device and utilizing design
control and strategic approaches to minimize
development risks and timeline.
• Design verifi cation, biocompatibility, extractable and
leachables
• Packaging and manufacturing consideration
• Stability and controls strategy
Reasons to Attend:
• Learn about interlinked relationship between drug
product, primary container, device, and packaging.
• Consideration and ways to minimize device
development risks
• Dive into design verifi cation, biocompatibility, EL, and
control strategies
• Role packaging play in successful combination
product
• Process development and consideration
About the workshop Leader:
Michael Song leads the Device Functionality, Safety
and Digital Connectivity group at MedImmune, a
Member of the AstraZeneca Group. In his current role,
he oversees device functionality; primary container
science and technology; biocompatibility; container
closure integrity testing; and digital connectivity. Prior
to his current role, Michael was head of Device and
Package Engineering at Adello Biologics, a member
of Amneal Pharmaceutical. He also has held key
engineering lead and toxicology SME positions at
Stryker, Kavlico, and other companies. Michael holds a
BS in Electrical Engineering from Purdue University and
PhD in Neuroscience and Toxicology from Iowa State
University.
Combination Product Development – A roadmap for success
Post conference WorksHoP a
08.30 - 12.00
Register online at www.pfsamericas.com
Post Conference Workshop Day
Wednesday 29th April 2020, Sheraton Boston Hotel, Boston, USA www.pfsamericas.com
Workshop Leader:
Michael Song, Senior Manager, Dosage Form Design
and Development, AstraZeneca
Post conference WorksHoP b
13.00 - 15.30
Drug Delivery Device Testing Solutions
Overview of the workshop:
In the drug delivery device, testing world, the regulatory
requirements add complexity to the simplest of test.
What occurs when the testing moves from the simple
to multifaceted is an exponential amount of effort to
meet industry demands. Finding the best partner starts
with a full understanding of your internal and external
requirements. Uncovering the unknowns is an arduous
task but a crucial one to your success.
About the workshop leader:
Michael Goehring, Medical Pharmaceutical
Industry Manager, ZwickRoell
BSEE – Instrumentation and Systems – University of
Connecticut Field Systems Engineer for materials
and component test systems Territory Manager
for Laboratory Information Management Systems
District and Regional Sales Manager for materials and
component test system North America Sales Manager
for material preparation and analysis Industry Manager
– Medical Pharmaceutical.
ZwickRoell has years of experience in delivering
innovative solutions for drug delivery systems that
reduce operator infl uence, which increases accuracy,
repeatability, reproducibility and traceability of test
results.
Post conference WorksHoP c
16.00 - 18.20
How to pass a Human Factors Validation study
Overview of the workshop:
Hear expert opinions on how to structure a human
factors program from product conceptualization and
early design through risk analysis development and
iterative usability testing in order to pass a human factors
validation study on the fi rst attempt.
Reasons to Attend:
• Learn how to build and optimize your company’s
human factors and usability engineering process
and how that can be applied to every development
project in order to reduce development delays and
improve the chances of fi rst-time success
• Discuss the regulatory imperative of HFE, and the focus
on use-related harm, as well as other uses of HFE
• Discuss how HFE as an RD activity, not a
documentation activity
• Discuss development and testing of instructions
for use (IFU)
• Discuss how to scale HFE programs and how programs
vary from product to product
About the workshop leaders:
Pati andMarc manage all aspects of human factors projects
at Core Human Factors. Our experience includes hundreds
of different types of medical devices and combination
products. We have worked on every phase of HF work, run
studies all around the world, and helped dozens of different
companies manage their HF programs and navigate
regulatory pathways. Part of our work includes IFU design,
development and testing.
Core Human Factors, Inc. (Core) is a consulting group
based outside of Philadelphia, PA, staffed by human
factors specialists with a wide variety of backgrounds. We
specialize in human factors testing for medical devices and
health care systems. Core has helped hundreds of products
successfully navigate FDA review and gain CE marks, and
our researchers have published dozens of publications in
peer-reviewed journals. In addition to user testing, we also
assist in the design of products, instructional materials, and
training programs; risk analyses; user needs documentation;
and ideation sessions to facilitate invention and human-
centered design in health care and medicine.
Programme
16.00 Scaling HFE - Doing More with Less
• Regulatory imperative and focus on safety
• Time and cost tradeoffs in iterative design
• Can you be a biosimilar or generic?
• Making changes after a Validation
16.35 Human Factors Protocols that Work
• Valid assessments of risks
• Non-biasing study designs and interview techniques
• Pivoting from a pilot
• Pre-submission process
17.10 Instructions for Use, a Human Factors Perspective
• Why IFUs should be considered early and often
• Initial design
• Iterative development
• The good, the bad, and the ugly
17.45 Case Studies
• Case study #1
• Case study #2
• Case study #3
• Case study #4
Programme
13.00 Drug Delivery Device Testing Overview
• Importance of a URS (User Requirements Specifi cation
• Functional Design Specifi cation
13.35 (Prefi lled) Syringe testing and spring simulation (power pack)
• Glide Force New ISO 7886-1
• ISO 11040-4, -6, -8
• ISO 80369-7, -20
14.10 Auto injector and pen injector testing – wearable device testing
• ISO 11608-1 (Pen), ISO 11608-2 (Needle), ISO 11608-3
(Cartridge)
• ISO 11608-2 (Needle)
• ISO 11608-3 (Cartridge)
• ISO 11608-5 (Full Function test on Auto Injectors)
• ISO 11608-6 (Wearables)
14.45 Device testing – regulatory demands
• 21 CFR Part 11 – Traceability (When, Who, What, Why
and Who is Responsible)
• DQ, IQ, OQ and why not PQ. MDR Europe
15.20 Session Recap
15.30 Afternoon Tea
Workshop Leader:
Michael Goehring, Medical Pharmaceutical
Industry Manager, ZwickRoell
Workshop Leaders:
Marc Egeth, PhD, Senior Director,
Core Human Factors, Inc.
Pati Anderson,
Mse, Senior Associate,
Core Human Factors, Inc.
Programme
08.30 Registration and Coffee
09.00 Session 1
• Primary Containers Components
• Drug Product and Primary Container interaction and
considerations
• Extractable and Leachables
09.35 Session 2
• Device selection and characterization
• Considerations from process, manufacturing, packaging,
and usability standpoint
• Key drivers for success and novel devices
10.10 Morning Coffee
10.30 Session 3
• Process and manufacturing overview considerations
(clinical, commercial, and automation)
• Packaging considerations and risk reduction
• Risk Assessment, Controls strategy and DV testing
11.05 Session 4
• Design Verifi cation and Validation
• Stability approaches
• Future trends, digital health, wearables, and novel technology
11.45 Session Recap
12.00 Networking Lunch

5.
ProudLy sPonsored by:
sPonsorsHiP and exHibition oPPortunities
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to compliment you company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specifi c
to your industry. Should you wish to join the increasing number of companies benefi ting from sponsoring our conference please call:
Alia Malick, Director, on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Marketing oPPortunities
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Jinna Sidhu, Marketing Manager, +44 (0) 20 7827 6088 or email: HSidhu@smi-online.co.uk
Pre-Filled Syringes East Coast Conference
www.pfsamericas.com
Register online at www.pfsamericas.com
Aptar Pharma is a leading provider of innovative drug delivery systems to pharmaceutical, consumer healthcare and biotech customers worldwide, enabling
safe, convenient and compliant medication delivery. Trusted partner of the pharmaceutical community, we provide our customers with a large range of
specialized drug delivery devices, components and analytical services backed by decades of proven expertise. We have broad therapeutic expertise in
Nasal, Pulmonary, Injectables, Eye Care and Dermal delivery routes, among others. Our global manufacturing footprint of sites in Argentina, China, France,
Germany, India, Switzerland and the U.S. provides security of supply and local support to our customers. www.aptar.com/pharma
Credence MedSystems is an innovator in injectable drug delivery devices. Credence’s philosophy of Innovation Without Change results in products
that impress and protect end-users while preserving pharma’s existing processes, sourcing strategies and preferred primary package components. The
Companion® family of syringe systems includes proprietary needle-retraction technology, reuse prevention and other critical safety and usability features in
Staked and Luer needle formats. The Dual Chamber platform offers single-step mixing and injection for drugs requiring reconstitution at the time of delivery.
Additional products such as metered dose devices, multi-length staked needles and other novel devices address the needs of specifi c therapeutic markets.
www.credencemed.com
Mitsubishi Gas Chemical is a leading company in the fi eld of oxygen barrier and absorbing technologies. Based on these technologies and experiences, we
have successfully developed multilayer plastic vial and syringe having excellent oxygen, ultra violet and water vapor barrier. The products make it possible to
replace glass with plastic for injectable drugs. www.mgc.co.jp/eng/products/abd/oxycapt.html
Polyplastics is the leading maker of TOPAS COC (cyclic olefi n copolymer), a glass-clear, incredibly pure, break-resistant plastic for drug delivery, including
syringes, vials and cartridges. The benign COC medical polymer presents a nonreactive surface for advanced molecules. Additionally, TOPAS COC offers
high moisture and chemical resistance, barrier and UV transmission. https://topas.com
STERIS Life Sciences is your trusted partner in contamination control. For over 100 years, STERIS has been a global leader and expert in the industries of
sterilization, cleaning and infection control. Today, we continue to build on this heritage by providing the products and resources you need throughout every
step of your process. From innovation to results, our comprehensive portfolio of products and services is designed to meet your needs. With offi ces located
worldwide and technicians in over 100 countries, you can count on us to be where you are when you need us, every step of the way. Trust STERIS Life Sciences
to help you create a healthier and safer world. www.sterislifesciences.com
The Weiss-Aug Group is your global partner for the design support, development, engineering and manufacture of medical devices and drug delivery
components and sub-assemblies. With specialized knowledge and state-of-the-art equipment, The Weiss-Aug group delivers the latest technologies for
Disposable Safety Products, Drug-Delivery Products, Orthodontics, Ophthalmic Disposables and Devices, Electrosurgery. www.weiss-aug.com/
ZEON’s Zeonex® and Zeonor® cyclo olefi n polymer (COP) allow for advanced, break-resistant syringes, vials and lyophilization containers for protein-based
biopharmaceuticals, high viscosity drugs, and contrast media. They also offer high purity, “glass-like” transparency, sterilization, low water absorption, and
superior moldability, as well as overcome protein adsorption and ph shift concerns. www.zeonex.com
ZwickRoell manufactures and supports a wide range of materials testing machines, systems and accessories for use in research, quality control, production
environments and academia. Our extensive portfolio of testing machines and accessories cover almost every segment, from medical and pharmaceutical
packaging to surgical instruments and orthopaedics and biomaterials. www.zwickroell.com
Pre-Filled Syringes East Coast
Past Attendee Breakdown
110+
Industry professionals
from Europe and beyond
7+
Dedicated hours
of networking
Business
Development
Manager 22%
Senior
Engineer
21%
Director 17%
Project
Manager
15%
Senior Device
Manager 12%
Senior Principal
Scientist 13%
Breakdown of attendee - Job function
suPPorted byofficiaL
Media Partner
key Media Partners
Attendee Geography:
USA
78%
Europe
12%
United
Kingdom 4%
Asia
Pacifi c 2%
Africa 1%
Canada
3%
Pre-Filled
Syringes Series
save tHe date
Conference:
October 2020
Sheraton Boston Hotel,
Boston, USA
Wearable Injectors and
Connected Devices
USA
Conference:
15th - 16th June 2020
Hyatt Regency Mission Bay,
San Diego, CA, USA
Pre Filled Syringes
West Coast
Conferences:
14th-15th September 2020
San Francisco, USA
Pre Filled Syringes
San Francisco
neW
for
2020
neW
for
2020

6.
PRE-FILLED SyRINGES EAST COAST 2020
Conference: Monday 27th Tuesday 28th April 2020, Sheraton Boston Hotel, Boston, USA
Workshops: Wednesday 29th April 2020, Sheraton Boston Hotel, Boston, USA
4 WAyS TO REGISTER
www.pfsamericas.com
fax your booking form to +44 (0) 870 9090 712
PHone on +44 (0) 870 9090 711
Post your booking form to: Events Team, SMi Group Ltd,
India House, 45 Curlew Street, London, SE1 2ND, UK
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Unique Reference Number
Our Reference P-315
docuMentation
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-315 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ uk bacs Sort Code 300009, Account 11775391
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOyDGB21013
IBAN GB75 LOyD 3000 0911 7753 91
□ Cheque We can only accept US Dollar Cheques drawn on a US Bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
PayMent
vat
VAT at 20% is charged on Document portal and literature distribution for all UK customers
and for those EU customers not supplying a registration number for their own country here.
□ Book by by 13th December to receive $400 off the conference price
□ Book by 31st January to receive $300 off the conference price
□ Book by 28th February to receive $200 off the conference price
earLy bird
discount
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefi ngs we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifi cally to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
accounts dePt
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
deLegate detaiLs
venue Sheraton Boston Hotel, Boston, USA
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
conference Prices grouP discounts avaiLabLe
I would like to attend: (Please tick as appropriate) TOTAL
□ Conference Workshop Day $2998.00
□ Conference only $1999.00
□ Workshop Day only $999.00
□ Evening Dinner (Limited Availability - only available to Pharmaceutical Companies)
ProMotionaL Literature distribution
□ Distribution of your company’s promotional
literature to all conference attendees $1598.00 + VAT $1917.60
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.